专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07744912B1 Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups 有权
标题翻译：通过亲核加成反应与共轭不饱和基团形成的生物材料
公开(公告)号：US07744912B1
公开(公告)日：2010-06-29
申请号：US09496231
申请日：2000-02-01
申请人： Jeffrey A. Hubbell , Donald Elbert , Matthias Lütolf , Alison Pratt , Ronald Schoenmakers , Nicola Tirelli , Brent Vernon
发明人： Jeffrey A. Hubbell , Donald Elbert , Matthias Lütolf , Alison Pratt , Ronald Schoenmakers , Nicola Tirelli , Brent Vernon
IPC分类号： A61F13/00 , A61L24/00 , A61L26/00 , A61L33/00 , C12N9/96
CPC分类号： A61K9/0024 , A61K9/06 , A61K47/6903 , A61L24/0031 , A61L24/043 , A61L26/0052 , A61L26/008 , A61L27/26 , A61L27/52 , A61L31/041 , A61L31/145 , C08G81/00 , Y10S524/916
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

2. 发明申请

US20090098083A1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS 有权
标题翻译：用于控制药物活性化合物递送的添加反应
公开(公告)号：US20090098083A1
公开(公告)日：2009-04-16
申请号：US12192655
申请日：2008-08-15
申请人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
发明人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： A61K47/48 , C08G63/91 , A61P17/02
CPC分类号： A61L27/52 , A61K47/60 , A61K47/6903 , C07H21/04 , C08G65/329 , C08G65/3322 , C12N5/0068 , C12N2501/585 , C12N2533/30
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

3. 发明授权

US07413739B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds 有权
标题翻译：药物活性化合物受控输送的共轭加成反应
公开(公告)号：US07413739B2
公开(公告)日：2008-08-19
申请号：US11257818
申请日：2005-10-25
申请人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
发明人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： A61K38/54 , A61K39/40 , A61K39/00 , C12Q1/68 , C07H21/00 , C12N9/96
CPC分类号： A61L27/52 , A61K47/60 , A61K47/6903 , C07H21/04 , C08G65/329 , C08G65/3322 , C12N5/0068 , C12N2501/585 , C12N2533/30
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

4. 发明授权

US06958212B1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds 有权
标题翻译：药物活性化合物受控输送的共轭加成反应
公开(公告)号：US06958212B1
公开(公告)日：2005-10-25
申请号：US09586937
申请日：2000-06-02
申请人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
发明人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： A61K38/54 , A61K39/40 , A61K47/48 , C07H21/04 , C12N9/96 , C12Q1/68
CPC分类号： A61L27/52 , A61K47/60 , A61K47/6903 , C07H21/04 , C08G65/329 , C08G65/3322 , C12N5/0068 , C12N2501/585 , C12N2533/30
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

5. 发明授权

US07291673B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds 有权
标题翻译：药物活性化合物受控输送的共轭加成反应
公开(公告)号：US07291673B2
公开(公告)日：2007-11-06
申请号：US10297229
申请日：2001-06-04
申请人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
发明人： Jeffrey A. Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： C08F290/14 , A61K47/48 , C12Q1/68 , C07H19/04 , A61K38/54 , A61K39/00
CPC分类号： A61K31/337 , A61K31/4745 , A61K31/56 , A61K31/704 , A61K31/7072 , A61K31/7088 , A61K47/60 , A61K47/62 , A61K47/6903 , A61K48/00
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

6. 发明授权

US07060681B2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids 有权
公开(公告)号：US07060681B2
公开(公告)日：2006-06-13
申请号：US10201547
申请日：2002-07-22
申请人： Jeffrey A. Hubbell , Ronald Schoenmakers , Heather D. Maynard
发明人： Jeffrey A. Hubbell , Ronald Schoenmakers , Heather D. Maynard
IPC分类号： A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , C07K5/0812 , C07K5/1008 , C07K5/1013 , C07K5/1021
摘要： The application describes ligands for binding targets, the ligands preferably including peptides having at least one sulfated or sulfonated amino acid. The ligand preferably specifically binds to heparin binding sites of biomolecules. Compositions, systems, and methods for making and using the ligands are described.

7. 发明授权

US07670605B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds 有权
标题翻译：药物活性化合物受控输送的共轭加成反应
公开(公告)号：US07670605B2
公开(公告)日：2010-03-02
申请号：US12192655
申请日：2008-08-15
申请人： Jeffrey A. Hubbell , Donald L. Elbert , Ronald Schoenmakers
发明人： Jeffrey A. Hubbell , Donald L. Elbert , Ronald Schoenmakers
IPC分类号： A61K39/00 , C12Q1/68 , C12N9/96 , C07H21/04
CPC分类号： A61L27/52 , A61K47/60 , A61K47/6903 , C07H21/04 , C08G65/329 , C08G65/3322 , C12N5/0068 , C12N2501/585 , C12N2533/30
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

8. 发明申请

US20060127352A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds 有权
标题翻译：药物活性化合物受控输送的共轭加成反应
公开(公告)号：US20060127352A1
公开(公告)日：2006-06-15
申请号：US11257818
申请日：2005-10-25
申请人： Jeffrey Hubbell , Donald Elbert , Ronald Schoenmakers
发明人： Jeffrey Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： A61K38/17 , A61K31/765 , A61K31/785 , C08G63/91
CPC分类号： A61L27/52 , A61K47/60 , A61K47/6903 , C07H21/04 , C08G65/329 , C08G65/3322 , C12N5/0068 , C12N2501/585 , C12N2533/30
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

9. 发明申请

US20110053880A1 COMPOSITION FOR TREATMENT OF TUBERCULOSIS 有权
标题翻译：用于治疗结肠癌的组合物
公开(公告)号：US20110053880A1
公开(公告)日：2011-03-03
申请号：US12808801
申请日：2008-11-25
申请人： Martin Fussenegger , Wilfried Weber , Ronald Schoenmakers
发明人： Martin Fussenegger , Wilfried Weber , Ronald Schoenmakers
IPC分类号： A61K31/7028 , A61K31/44 , A61K31/175 , G01N33/53 , A61P31/06
CPC分类号： A61K31/17 , A61K31/4409 , A61K45/06 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N═CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.
摘要翻译：本发明涉及包含防止EthR与ethA启动子结合的化合物的药物组合物，例如式1的化合物，其中R 1是任选取代的苯基或任选取代的吡啶基; R2（CH2）n，其中n为1,2,3或4; R3是CH3（CH2）m，其中m是0,1,2或3; X 1是O，S，NH，N（CH 3）或CH 2; X2是O，S或NH; 特别是丁酸2-苯基乙酯和式2的硫代酰胺或硫脲，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。药物组合物可用于例如治疗多重耐药性结核病。

10. 发明授权

US09050295B2 Composition for treatment of tuberculosis 有权
标题翻译：用于治疗结核病的组合物
公开(公告)号：US09050295B2
公开(公告)日：2015-06-09
申请号：US12808801
申请日：2008-11-25
申请人： Martin Fussenegger , Wilfried Weber , Ronald Schoenmakers
发明人： Martin Fussenegger , Wilfried Weber , Ronald Schoenmakers
IPC分类号： A61K31/17 , A61K31/4409 , A61K45/06
CPC分类号： A61K31/17 , A61K31/4409 , A61K45/06 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N═CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.
摘要翻译：本发明涉及包含防止EthR与ethA启动子结合的化合物的药物组合物，例如式1的化合物，其中R 1是任选取代的苯基或任选取代的吡啶基; R2（CH2）n，其中n为1,2,3或4; R3是CH3（CH2）m，其中m是0,1,2或3; X 1是O，S，NH，N（CH 3）或CH 2; X2是O，S或NH; 特别是丁酸2-苯基乙酯和式2的硫代酰胺或硫脲，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。药物组合物可用于例如治疗多重耐药性结核病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式